Mutations in the ARID1a gene, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. But this mutated gene may also strengthen specific cancer drugs’ ability to treat certain tumors, according to a team of MD Anderson researchers.
他们的研究报告发表在癌症发现，发现，ARID1A某些突变敏感一些肿瘤对PARP抑制剂的药物，如...
It’s the Friday before Father’s Day, and V. Craig Jordan, Ph.D., who’s considered the “Father of Tamoxifen,” is sitting down to talk about...
The first national review of breast-conserving therapy (BCT) shows that over the last 13 years, rates of this treatment for early-stage breast cancer have increased at a steady pace. However, the review also highlights demographic factors that impact whether or not a patient will have access to BCT. MD Anderson researchers found that disparities related to age, treatment facility type and geographic region, are declining. But they also...
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic...
通过Epstein-Barr病毒表达的分子在患有慢性淋巴细胞性白血病B细胞，骨髓和等离子体被发现...